Nivolumab in children and young adults with relapsed/refractory solid tumors (ADVL1412): A Phase 1 / 2 Trial

BACKGROUND: Immune checkpoint inhibitors targeting PD-1 have demonstrated clinical benefit in adults with cancer, but experience is limited in children. We conducted a Phase 1/2 study of nivolumab, a PD-1 blocking monoclonal antibody, to determine its safety, pharmacokinetics, and efficacy in childr...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Lancet Oncol
Hlavní autoři: Davis, Kara L., Fox, Elizabeth, Merchant, Melinda S., Reid, Joel M., Kudgus, Rachel A., Liu, Xiaowei, Minard, Charles G., Voss, Stephan, Berg, Stacey L., Weigel, Brenda J., Mackall, Crystal L.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2020
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7255545/
https://ncbi.nlm.nih.gov/pubmed/32192573
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(20)30023-1
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky